Tablet use before bed could spell trouble for sleep patterns

The use of light-emitting tablets near bedtime could delay sleep, suppress melatonin production and hinder next-morning alertness, according to a study published May 22 in Physiological Reports.

Getting a full night’s sleep is important for health, but the devices could be disrupting rest cycles. In this study, researchers examined the effects of using a light-emitting tablet close to bedtime to gain insight into how it could be affecting rest.

 

“Rapid technological advances and market pressures have led to near ubiquitous use of LE‐devices (e.g., desktop, laptop, and tablet computers, cell/smart phones, televisions, and video games) in the modern home and workplace; and such devices are now integral to many daily functions including communication, commerce, recreation and access to news and information,” wrote co-author Jeanne Duffy, of Brigham and Women's Hospital and Harvard Medical School, and colleagues. “Greater utility, availability, and portability of LE‐devices have additionally led to widespread LE‐device use in the evening and incorporation into the bedtime routine.”

The study included nine healthy adults who were tested for five consecutive evenings. Each night, participants either used a tablet to do whatever they wanted or read printed materials. Researchers noted that, on tablet use nights, participants went to sleep a half hour later. Additionally, participants had reduced melatonin levels and a delay of melatonin secretion. Tablet users rated their next-morning alertness as lower.

"These findings provide more evidence that light-emitting electronic devices have biological effects," said Duffy. "Using light-emitting electronic devices in the late evening can postpone our decision to go to sleep and make us sleepier the next morning."

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.